Targeting metastatic colorectal cancer – present and emerging treatment options

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• LynchJPHoopsTCThe genetic pathogenesis of colorectal cancerHematol Oncol Clin North Am200216477581012418049
   PubMed Web of Science ®Google Scholar
• FearonERVogelsteinBA genetic model for colorectal tumorigenesisCell19906157597672188735
   PubMed Web of Science ®Google Scholar
• WeisenbergerDJSiegmundKDCampanMCpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNat Genet200638778779316804544
   PubMed Web of Science ®Google Scholar
• NoffsingerAESerrated polyps and colorectal cancer: new pathway to malignancyAnnu Rev Pathol2009434336419400693
   PubMed Web of Science ®Google Scholar
• RajagopalanHBardelliALengauerCKinzlerKWVogelsteinBVelculescuVETumorigenesis: RAF/RAS oncogenes and mismatch-repair statusNature2002418690193412198537
   PubMed Web of Science ®Google Scholar
• DomingoENiessenRCOliveiraCBRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genesOncogene200524243995399815782118
   PubMed Web of Science ®Google Scholar
• Van CutsemEKöhneCHHitreECetuximab and chemotherapy as initial treatment for metastatic colorectal cancerN Engl J Med2009360141408141719339720
   PubMed Web of Science ®Google Scholar
• Van CutsemEKöhneCHLángICetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation statusJ Clin Oncol201129152011201921502544
   PubMed Web of Science ®Google Scholar
• SobreroAFMaurelJFehrenbacherLEPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancerJ Clin Oncol200826142311231918390971
   PubMed Web of Science ®Google Scholar
• BokemeyerCBondarenkoIMakhsonAFluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancerJ Clin Oncol200927566367119114683
   PubMed Web of Science ®Google Scholar
• DouillardJYSienaSCassidyJRandomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJ Clin Oncol201028314697470520921465
   PubMed Web of Science ®Google Scholar
• DouillardJYSienaSTaberneroJOverall survival analysis from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC)J Clin Oncol201331Suppl abstr 3620
   Google Scholar
• PeetersMPriceTJCervantesARandomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerJ Clin Oncol201028314706471320921462
   PubMed Web of Science ®Google Scholar
• JonkerDJO’CallaghanCJKarapetisCSCetuximab for the treatment of colorectal cancerN Engl J Med2007357202040204818003960
   PubMed Web of Science ®Google Scholar
• Van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol200725131658166417470858
   PubMed Web of Science ®Google Scholar
• PriceTJPeetersMKimTWASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC)Eur J Cancer201349Suppl 3 LBA 18
   Google Scholar
• YeLCLiuTSRenLRandomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastasesJ Clin Oncol201331161931193823569301
   PubMed Web of Science ®Google Scholar
• HeinemannVvon WeikersthalLFDeckerTRandomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3)J Clin Oncol201331Suppl abstr LBA3506
   PubMedGoogle Scholar
• VenookAPBlankeCDNiedzwieckiDCancer and Leukemia Group B/Southwest Oncology Group Trial 80405: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinomaClin Colorectal Cancer20055429229416356309
   PubMed Web of Science ®Google Scholar
• VenookAPBlankeCDNiedzwieckiDRevisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinomaClin Colorectal Cancer20076753653817553204
   PubMed Web of Science ®Google Scholar
• DouillardJYOlinerKSSienaSPanitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancerN Engl J Med2013369111023103424024839
   PubMed Web of Science ®Google Scholar
• StintzingSJungARossiusLAnalysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patientsEur J Cancer201349Suppl 3LBA17
   Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• FuchsCSMarshallJMitchellERandomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C StudyJ Clin Oncol200725304779478617947725
   PubMed Web of Science ®Google Scholar
• HochsterHSHartLLRamanathanRKSafety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE studyJ Clin Oncol200826213523352918640933
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDíaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• FuchsCSMarshallJBarruecoJRandomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C studyJ Clin Oncol200826468969018235136
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJEastern Cooperative Oncology Group Study E3200Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• GrotheyASugrueMMPurdieDMBevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)J Clin Oncol200826335326533418854571
   PubMed Web of Science ®Google Scholar
• CohnALBekaii-SaabTSBendellJCClinical outcomes in bevacizumab(BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP)J Clin Oncol201028Suppl 15 abstr 3596
   Web of Science ®Google Scholar
• BennounaJSastreJArnoldDML18147 Study InvestigatorsContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• MasiGVasileELoupakisFRandomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysisJ Natl Cancer Inst20111031213021123833
   PubMedGoogle Scholar
• FalconeARicciSBrunettiIGruppo Oncologico Nord OvestPhase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord OvestJ Clin Oncol200725131670167617470860
   PubMed Web of Science ®Google Scholar
• SouglakosJAndroulakisNSyrigosKFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)Br J Cancer200694679880516508637
   PubMed Web of Science ®Google Scholar
• FalconeACremoliniCMasiGFOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO groupJ Clin Oncol201331Suppl abstr 3505
   Google Scholar
• LoupakisFCremoliniCMasiGFOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trialJ Clin Oncol201231Suppl 4 abstr 336
   Google Scholar
• KoopmanMSimkinsLHTijeAJMaintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer GroupJ Clin Oncol201331Suppl abst 3502
   Google Scholar
• PuntCJASimkensLHJMayAUpdated results including quality of life of the phase III CAIRO3 study of the Dutch Colorectal Cancer Group: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancerEur J Cancer201349Suppl 3 abstr 2166
   Google Scholar
• JohnssonAHagmanHFrödinJEA randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trialAnn Oncol20132492335234123788755
   PubMed Web of Science ®Google Scholar
• HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
   PubMed Web of Science ®Google Scholar
• Van CutsemETaberneroJLakomyRAddition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimenJ Clin Oncol201230283499350622949147
   PubMed Web of Science ®Google Scholar
• TaberneroJVan CutsemELakomýRAflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trialEur J Cancer201450232033124140268
   PubMed Web of Science ®Google Scholar
• WilhelmSMDumasJAdnaneLRegorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInt J Cancer2011129124525521170960
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroACORRECT Study GroupRegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular characterization of human colon and rectal cancerNature2012487740733033722810696
   PubMed Web of Science ®Google Scholar